Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

心达悦 - NMPA Drug Approval Details

Approvals/NMPA/Vortioxetine Hydrobromide Tablets

Approved

化学药品

Vortioxetine Hydrobromide Tablets

H. Lundbeck A/S🇨🇳 National Medical Products Administration

Approval Date: Jul 29, 2022
Approval ID: a7e26639bbdd7b9a
Company: H. Lundbeck A/S
Type: 化学药品

Approval Details

Approval Id: a7e26639bbdd7b9a
Approval Number: 国药准字HJ20170382
Generic Name: 氢溴酸伏硫西汀片
Generic Name En: Vortioxetine Hydrobromide Tablets
Trade Name: 心达悦
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 5mg(以C₁₈H₂₂N₂S计)
Reg Date: 2022-07-29
Expired Date: 2027-07-28
Company Name: H. Lundbeck A/S
Production Company Name: H. Lundbeck A/S
Company Detail Path: /organization/h-lundbeck-a-s
Production Company Detail Path: /organization/h-lundbeck-a-s

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Jul 29, 2022

Approval ID

a7e26639bbdd7b9a

Type

化学药品

Back to NMPA Approvals